Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study

OBJECTIVES: The antitumor activity of nivolumab plus regorafenib in colorectal cancer from a phase Ib REGONIVO study is encouraging. The present study was conducted to evaluate the efficacy and safety of regorafenib or fruquintinib plus sintilimab as third-line or above therapy in patients with micr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Caiyun, Lv, Huifang, Chen, Beibei, Xu, Weifeng, Wang, Jianzheng, Liu, Yingjun, Wang, Saiqi, Zhao, Jing, He, Yunduan, Chen, Xiaobing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549285/
https://www.ncbi.nlm.nih.gov/pubmed/36226061
http://dx.doi.org/10.3389/fonc.2022.917353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549285/
https://www.ncbi.nlm.nih.gov/pubmed/36226061
http://dx.doi.org/10.3389/fonc.2022.917353

Ejemplares similares